Monday, September 10, 2012

FDA endorses Pfizer Inc. (NYSE:PFE) drug for treating atypical blood cancer

FDA has declared their endorsement of a new Pfizer Inc.(NYSE:PFE) drug as an authentic antidote for treatment of rare group of blood cancer as they have certified this medicine effective for treatment of a rare group of bone marrow and blood cancer disease. The name of the drug is Bosulif.

Research and study on the administration on Bosulif has revealed the fact this daily pill can effectively treat chronic myeloid leukemia; in this carcinogenic disease patients becomes career of a specific genetic variation. Mainly senior people are affected by this type of blood cancer where bone marrow becomes an unhealthy producer of white cells which cause problem for normal cells to grow resulting in weak immunity power of the patient. Administration of Bosulif can block an enzyme named tyrosine kinase, which is known as a trigger for mass production of these unhealthy white cells. Dumping of these harful white blood cells are extremely harmful for elimination of cancer related complications.

Get Free Trend Analysis On PFE

FDA has recommended Bosulif for the patients who are non-responsive toward general cancer therapies including Novartis' Gleevec as well as for those cancer patients having genetic mutation related disorder called Philadelphia chromosome. The percentage for this patients are 15% out of blood cancer disease but these patients are found non responsive to drug treatments so far, with Bosulif there is a possibility of their physical improvement, FDA has recommended.

According to FDA statistics, almost 5,430 patients will be diagnosed with chronic myelogenous leukemia by this current year; as per the Pfizer study showing 34% patients treated with this drug showed positive response after 6 months of treatment with this pill. While being treated with Gleeve 33% patient shows positive result by 48 weeks while 50% of patients showed positive result on administration of Bosulif without any problem of Leukemia within that period.

The common side effects seen in the patients are nausea, diarrhea, pain in abdomen, mild fever, and rash, although none of these side effects are found too acute.

No comments:

Post a Comment

Privacy Policy | Legal Disclaimer